cefaclor anhydrous has been researched along with Intestinal Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alper Öztürk, A; Aygül, A; Namlı, İ | 1 |
1 other study(ies) available for cefaclor anhydrous and Intestinal Diseases
| Article | Year |
|---|---|
Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cefaclor; Coinfection; COVID-19; Drug Compounding; Escherichia coli; Excipients; Intestinal Diseases; Kinetics; Microbial Sensitivity Tests; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Polymethacrylic Acids; Staphylococcus aureus | 2021 |